Globus Medical, Inc. (GMED): Price and Financial Metrics


Globus Medical, Inc. (GMED): $59.57

0.06 (+0.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

GMED POWR Grades

  • GMED scores best on the Quality dimension, with a Quality rank ahead of 90.97% of US stocks.
  • The strongest trend for GMED is in Growth, which has been heading up over the past 177 days.
  • GMED ranks lowest in Momentum; there it ranks in the 30th percentile.

GMED Stock Summary

  • GMED's current price/earnings ratio is 37.46, which is higher than 86.01% of US stocks with positive earnings.
  • The ratio of debt to operating expenses for GLOBUS MEDICAL INC is higher than it is for about only 0.45% of US stocks.
  • GMED's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 9.45% of US stocks.
  • Stocks that are quantitatively similar to GMED, based on their financial statements, market capitalization, and price volatility, are LMAT, LOGI, MMSI, CRTO, and FOXF.
  • Visit GMED's SEC page to see the company's official filings. To visit the company's web site, go to www.globusmedical.com.

GMED Valuation Summary

  • In comparison to the median Healthcare stock, GMED's price/sales ratio is 215.79% higher, now standing at 6.
  • GMED's price/earnings ratio has moved up 19.2 over the prior 123 months.

Below are key valuation metrics over time for GMED.

Stock Date P/S P/B P/E EV/EBIT
GMED 2022-09-23 6.0 3.4 37.4 30.6
GMED 2022-09-22 5.9 3.4 37.1 30.3
GMED 2022-09-21 6.0 3.5 37.9 31.0
GMED 2022-09-20 6.2 3.5 38.8 31.8
GMED 2022-09-19 6.2 3.5 38.8 31.7
GMED 2022-09-16 6.2 3.6 39.1 32.0

GMED Growth Metrics

    The 4 year cash and equivalents growth rate now stands at 83.9%.
  • The 2 year revenue growth rate now stands at 21.22%.
  • Its 3 year cash and equivalents growth rate is now at 76.79%.
GMED's revenue has moved up $184,897,000 over the prior 18 months.

The table below shows GMED's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 973.939 235.088 154.991
2022-03-31 961.307 257.394 141.946
2021-12-31 958.102 276.274 149.191
2021-09-30 941.526 280.205 187.042
2021-06-30 927.903 256.191 184.047
2021-03-31 825.809 220.07 121.665

GMED's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GMED has a Quality Grade of B, ranking ahead of 90.91% of graded US stocks.
  • GMED's asset turnover comes in at 0.547 -- ranking 84th of 186 Medical Equipment stocks.
  • OFIX, SRTS, and ESMC are the stocks whose asset turnover ratios are most correlated with GMED.

The table below shows GMED's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.547 0.745 0.189
2021-03-31 0.514 0.729 0.131
2020-12-31 0.512 0.724 0.111
2020-09-30 0.510 0.732 0.103
2020-06-30 0.504 0.741 0.096
2020-03-31 0.542 0.764 0.165

GMED Stock Price Chart Interactive Chart >

Price chart for GMED

GMED Price/Volume Stats

Current price $59.57 52-week high $81.78
Prev. close $59.51 52-week low $52.60
Day low $59.29 Volume 694,600
Day high $61.78 Avg. volume 683,268
50-day MA $61.08 Dividend yield N/A
200-day MA $65.43 Market Cap 5.93B

Globus Medical, Inc. (GMED) Company Bio


Globus Medical focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company was founded in 2003 and is based in Audubon, Pennsylvania.


GMED Latest News Stream


Event/Time News Detail
Loading, please wait...

GMED Latest Social Stream


Loading social stream, please wait...

View Full GMED Social Stream

Latest GMED News From Around the Web

Below are the latest news stories about GLOBUS MEDICAL INC that investors may wish to consider to help them evaluate GMED as an investment opportunity.

Here's Why Investors Should Retain Globus Medical (GMED) For Now

Investors are optimistic about Globus Medical's (GMED) better-than-expected results and new product introductions.

Yahoo | September 15, 2022

Globus Medical (GMED) Gains Market Share, Cost Woes Stay

Globus Medical (GMED) U.S. sales increase, driven by competitive rep conversions and robotic pull-through.

Yahoo | September 12, 2022

Could Globus Medical Be the Best Healthcare Stock?

Motley Fool contributor, Zane Fracek, explains why Globus Medical (NYSE: GMED) could be a long-term winner. Globus offers a balance between a stalwart medical devices company and a high-growth bet on tech and robotics.

Yahoo | September 6, 2022

Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around

What are the early trends we should look for to identify a stock that could multiply in value over the long term...

Yahoo | September 3, 2022

Globus Medical (GMED) Q2 Earnings Beat, Gross Margin Dips

Globus Medical's (GMED) Musculoskeletal Solutions products generate solid revenues on growth in spine and trauma implant portfolios.

Yahoo | August 5, 2022

Read More 'GMED' Stories Here

GMED Price Returns

1-mo 1.69%
3-mo 3.21%
6-mo -20.99%
1-year -24.59%
3-year 19.93%
5-year 96.08%
YTD -17.49%
2021 10.70%
2020 10.77%
2019 36.04%
2018 5.30%
2017 65.66%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7189 seconds.